Institutional investors hold a majority ownership of IMGN through the 89.32% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 323.3 Thousand shares of ImmunoGen Inc